QGEN

QIAGEN N.V. to release results for Q1 2024 and hold webcast

Retrieved on: 
Tuesday, April 9, 2024
Webcast, QIA, Conference, Conference call, QGEN, Frankfurt Stock Exchange, QIAGEN

Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024.

Key Points: 
  • Venlo, The Netherlands, April 09, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2024.
  • Press release date / time: Monday, April 29, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
  • Conference call date / time: Tuesday, April 30, at 15:00 Frankfurt time / 14:00 London time / 09:00 New York time.
  • Access the audio webcast - Click here: Access Webcast
    A conference call replay will be available by using the following link:

QIAGEN strengthens its portfolio for cancer research, showcasing latest product launches at AACR Annual Meeting 2024

Retrieved on: 
Wednesday, April 3, 2024
EGFR, Gene, Nested polymerase chain reaction, Professor, Cancer Institute, Circulating free DNA, Neoplasm, TCR, Research institute, QGEN, Research, PCR, Central business district, NGS, DNA, BRAF, Diagnosis, WIA, Cancer, Immune system, Liquid biopsy, UMI, Mutation, Genetics, Human genetics, Senior, AACR, Medical school, QIAGEN, Poster, Environment, IVD, Urine

Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.

Key Points: 
  • Two Exhibitor Spotlight Theater sessions and several poster presentations will highlight additional advances from QIAGEN in this field.
  • EGFR and BRAF are genes essential for normal cell growth and function, but mutations in these genes can result in cancer development.
  • To advance research on how the immune system interacts with cancer, QIAGEN has introduced the QIAseq Targeted RNA-seq Panel for T-cell receptors.
  • Learn more about QIAGEN’s offering at the AACR Annual Meeting 2024, (booth #922 in the San Diego Convention Center) and poster presentations highlighting new solutions in digital PCR, NGS and preanalytical workflows at https://www.qiagen.com/applications/cancer-research/aacr-2024-annual-mee... .

QIAGEN introduces QIAstat-Dx Analyzer 2.0 with remote test results access, enhancing collaboration across healthcare system

Retrieved on: 
Monday, March 25, 2024
PCR, Comment, Patient, Software, Epidemiology, RAM, Senior, QIAGEN, QGEN, Medical device

The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces the Remote Results Application, still unique in the syndromic testing space.

Key Points: 
  • The upgraded diagnostic system, powered by the new QIAstat-Dx Operational Module PRO with a 64‑bit processor and 4GB of RAM, introduces the Remote Results Application, still unique in the syndromic testing space.
  • The new feature, accessible through the QIAsphere cloud and exclusively available with QIAstat‑Dx Analyzer 2.0, allows users to view, comment and confirm diagnostic test results directly from their desktop and mobile devices in any location, facilitating seamless collaboration across the healthcare system.
  • This enables greater flexibility and collaboration between central and regional labs, especially in decentralized testing, reducing diagnostic processing time and ensuring patients receive accurate results more quickly.
  • Alternatively, the QIAstat-Dx Analyzer 2.0 enables in-house visibility of test results over a shared network.

QIAGEN partners with International Panel Physicians Association to increase awareness of tuberculosis screening requirements

Retrieved on: 
Monday, March 18, 2024
BCG, IGRA, Disease, Infection, Tuberculosis, World Tuberculosis Day, Incidence, Partnership, Molecular diagnostics, Interferon gamma release assay, CPD, Patient, Ageing, Epidemiology, Genetically modified bacteria, Senior, TST, IPPA, MPH, CDC, Vaccination, QIAGEN, Gold, WHO, TB, Physician, QGEN

Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.

Key Points: 
  • Germantown, Maryland, and Venlo, the Netherlands, March 18, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a partnership with the International Panel Physicians Association (IPPA) to support and educate panel physicians around the globe on the latest tuberculosis (TB) screening requirements.
  • A special focus will be on the new Interferon Gamma Release Assay (IGRA) requirements and the associated benefits for patients and healthcare providers.
  • This collaboration follows the U.S. Centers for Disease Control and Prevention (CDC) updating its guidelines for new TB screening requirements for immigrants to the United States.
  • Alexandra Ortega, MPH, MCHES, Executive Director of the IPPA, said, “Working together with QIAGEN allows us to educate panel physicians on the latest TB screening requirements, ensuring patients receive the most accurate and efficient testing available.

QIAGEN announces Form 20-F annual report filing for 2023 results

Retrieved on: 
Monday, March 11, 2024
QIAGEN, QGEN, Annual report

Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission.

Key Points: 
  • Venlo, the Netherlands, March 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended December 31, 2023, with the U.S. Securities and Exchange Commission.
  • The document can be accessed on QIAGEN’s website here .
  • QIAGEN will provide printed copies of the 2023 Annual Report to shareholders free of charge upon request.
  • To obtain a printed copy of the 2023 Annual Report please use our contact form or send an email to [email protected] .

QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery

Retrieved on: 
Tuesday, February 27, 2024
Senior, AI, QGEN, Knowledge, QIAGEN, Drug discovery, Data, Biomedicine, Biomarker, Gene, Literature, Medical device

This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.

Key Points: 
  • This new offering is designed for data scientists and bioinformaticians who are looking for the most comprehensive knowledge graphs to fuel data-driven drug discovery.
  • QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources.
  • QIAGEN Biomedical KB-AI provides the most complete picture of biomedical relationships, including edge cases and novel relationships.
  • While QIAGEN Biomedical KB-HD is manually curated and known for its high quality and accuracy, QIAGEN Biomedical KB-AI contains over 25x more relationships, allowing data scientists to generate new insights.

QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification

Retrieved on: 
Tuesday, February 27, 2024
Senior, AI, QGEN, Knowledge, QIAGEN, Drug discovery, Data, Biomedicine, Biomarker, Gene, Literature, Medical device

QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources.

Key Points: 
  • QIAGEN Biomedical KB-AI is built on a massive dataset of biomedical literature and other scientific sources.
  • It identifies and extracts causal relationships between genes, diseases, drugs and other biological entities with AI, generating over 600 million more biomedical relationships than its complement, QIAGEN Biomedical KB-HD.
  • QIAGEN Biomedical KB-AI provides the most complete picture of biomedical relationships, including edge cases and novel relationships.
  • While QIAGEN Biomedical KB-HD is manually curated and known for its high quality and accuracy, QIAGEN Biomedical KB-AI contains over 25x more relationships, allowing data scientists to generate new insights.

QIAGEN earns ACT Label for new eco-friendlier QIAwave products and achieves first My Green Lab Platinum certification

Retrieved on: 
Thursday, February 15, 2024
ACT, Senior, Research, Platinum, QGEN, Targets, QIAGEN, Risk, Accountability, Certification, Science Based Targets initiative, MSCI, Sample, Science, GHG, Environmental issues

These new kits are the QIAwave RNA Plus Mini Kit and QIAwave DNA/RNA Mini Kit that are used in labs around the world.

Key Points: 
  • These new kits are the QIAwave RNA Plus Mini Kit and QIAwave DNA/RNA Mini Kit that are used in labs around the world.
  • In awarding the ACT (Accountability, Consistency, and Transparency) labels, My Green Lab found that the two new QIAwave products had an up to 27% improvement in the Environmental Impact Factor when compared to the respective QIAGEN standard kits.
  • QIAGEN’s R&D lab for Sample technologies at its European operational headquarters in Hilden, Germany, has achieved the Platinum certification level in a review by My Green Lab.
  • QIAGEN has set a roadmap to have all of its Life Sciences labs at the Hilden site certified by My Green Lab.

QIAGEN exceeds outlook for Q4 2023, led by 8% CER sales growth in non-COVID products and improved operational profitability

Retrieved on: 
Tuesday, February 6, 2024
EPS, Policy, COVID-19, Growth, Table, GAAP, Pressure, PDF, FY, QGEN, Tax, Molecular diagnostics, Public expenditure, Investment, CER, QIAGEN, Plant, Share repurchase, Forecasting

Net sales results of $503 million at constant exchange rates (CER) for Q4 2023 achieved the outlook for at least $500 million CER, driven by 8% CER growth in the non-COVID-19 portfolio.

Key Points: 
  • Net sales results of $503 million at constant exchange rates (CER) for Q4 2023 achieved the outlook for at least $500 million CER, driven by 8% CER growth in the non-COVID-19 portfolio.
  • Total sales for Q4 2023 rose 2% (+1% CER) to $509 million from Q4 2022, a period marked by significant COVID-19 sales.
  • Full-year 2023 sales declined 8% to $1.97 billion, achieving the outlook for $1.97 billion CER sales and were supported by 8% CER growth for non-COVID product groups.
  • For 2024, QIAGEN has set an outlook for net sales of at least $2.0 billion CER.

QIAGEN announces partnership with Penn State University to advance microbiome sciences

Retrieved on: 
Thursday, January 25, 2024
Senior, Student, Chitin, NGS, Research, Microbiome, Arthropod, Animal, Health, RNA, Partnership, Joint, Spider, Faculty, Genetics, Pennsylvania State University, Skeleton, Real-time, Environment, Bacteria, Arbovirus, Human, Reproduction, Entomology, Dengue fever, State College, Pennsylvania, Laboratory, Zika virus, QIAGEN, MITES, Virus, Organization, Wolbachia, Plant, PCR, Automation, Ecology, Education, QGEN, Nested polymerase chain reaction, Fungus, Antibiotics

Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.

Key Points: 
  • Germantown, Maryland, and State College, Pennsylvania, Jan. 25, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a first-in-kind collaboration with Penn State University in the United States to create a shared research and education facility for the fast-developing microbiome sciences.
  • In doing so, this new partnership will provide QIAGEN with a site to support the development of new products as a testing center.
  • This includes an internship program for graduate students from Penn State at QIAGEN laboratories at the European operational headquarters in Hilden, Germany, and helps them prepare for careers in the biotechnology industry.
  • “Additionally, it will foster relationships with the microbiome research community and enable us to better develop new products for microbiome research based on direct customer feedback.”
    Seth Bordenstein, Director of the One Health Microbiome Center, Professor of Biology and Entomology, and Huck Endowed Chair in the Microbiome Sciences, at Penn State said: “The ‘One Health’ vision shared by QIAGEN and Penn State University is critical for microbiome research.